9 recruiting, 2 active not recruiting. 11 Phase 1, 5 Phase 2.
By phase and status
Follow Elranatamab: new trials by email Literature Review of Elranatamab trials Research Report on Elranatamab
Trials (filtered) newest first · largest first
All 11 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects Cemsidomide, Elranatamab - Multiple Myeloma (MM) Phase 1 Recruiting 60 2026-02-06 2026-10-30
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma Elranatamab, Mezigdomide, Dexamethasone - Multiple Myeloma Phase 1 / Phase 2 Recruiting 62 2025-10-07 2026-09-02
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma Elranatamab, GM-CSF, DC/MM Fusion Vaccine - Multiple Myeloma, Relapse Multiple Myeloma Phase 1 Recruiting 25 2025-01-31 2026-05-07
Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma Elranatamab, Mezigdomide, Dexamethasone - Relapsed Refractory Multiple Myeloma (RRMM) Phase 1 / Phase 2 Recruiting 75 2024-11-26 2025-12-03
Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis Elranatamab - AL Amyloidosis Phase 1 / Phase 2 Recruiting 49 2024-11-01 2026-08-19
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma BMS-986393, Alnuctamab, Mezigdomide - Multiple Myeloma Phase 1 Recruiting 187 2024-02-22 2026-07-16
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) Elranatamab, Iberdomide - Multiple Myeloma Phase 1 Active not recruiting 100 2024-02-20 2026-09-15
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma AZD0305, Elranatamab, Pomalidomide - Multiple Myeloma Phase 1 / Phase 2 Recruiting 226 2023-12-05 2026-10-30
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) Cevostamab, Elranatamab, Tocilizumab - Relapsed or Refractory Multiple Myeloma Phase 1 Recruiting 120 2023-08-10 2026-11-05
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma Elranatamab, Carfilzomib, Maplirpacept - Multiple Myeloma Phase 1 Active not recruiting 59 2022-12-14 2026-08-13
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies CCS1477, Pomalidomide, Dexamethasone - Haematological Malignancy, Acute Myeloid Leukemia Phase 1 / Phase 2 Recruiting 250 2019-08-09 2026-06-24
Conditions studied Multiple Myeloma (10) · Recurrence (4) · Bites and Stings (1) · Hematologic Neoplasms (1) · Immunoglobulin Light-chain Amyloidosis (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell, Peripheral (1)
Sponsors Pfizer (2) · AstraZeneca (1) · C4 Therapeutics, Inc. (1) · Celgene (1) · CellCentric Ltd. (1) · Dana-Farber Cancer Institute (1) · David Avigan (1) · Genentech, Inc. (1) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (1) · YOUNGIL KOH (1)
Countries United States (9) · Canada (4) · Australia (3) · Spain (3) · United Kingdom (3) · China (2) · France (2) · Germany (2) · Israel (2) · South Korea (2) · Brazil (1) · Greece (1) · Japan (1) · Norway (1) · Singapore (1)
Top investigators David Avigan, MD (1) · Giada Bianchi (1) · Tim Somervaille (1)
NIH funding 2023 (2) , 2025 (1)